NTLA: Intellia Therapeutics, Inc.
About
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Current Value
$14.151 Year Return
Current Value
$14.151 Year Return
Key Details
Market Cap
$1.44B
P/E Ratio
-2.59
1Y Stock Return
-50.35%
1Y Revenue Growth
-16.77%
Dividend Yield
0.00%
Price to Book
1.5
Strategies that include NTLA
Stock's related to NTLA
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| BEAM | 67.35% | $2.09B | -9.52% | 0.00% |
| EDIT | 64.54% | $204.72M | -75.49% | 0.00% |
| CRSP | 62.21% | $4.01B | -30.49% | 0.00% |
| PATK | 57.00% | $2.90B | +54.53% | 1.67% |
| LAD | 56.81% | $9.87B | +38.08% | 0.56% |
| VSH | 56.38% | $2.07B | -31.61% | 2.64% |
| SKY | 55.27% | $5.67B | +68.31% | 0.00% |
| HASI | 54.87% | $3.29B | +16.65% | 5.90% |
| HST | 54.78% | $12.11B | +1.49% | 4.66% |
| RXRX | 54.64% | $1.80B | -4.13% | 0.00% |
| ALLO | 54.62% | $444.50M | -24.82% | 0.00% |
| DNLI | 54.36% | $3.50B | +33.66% | 0.00% |
| EEFT | 53.58% | $4.44B | +16.88% | 0.00% |
| DX | 53.32% | $991.29M | +9.75% | 12.54% |
| PEB | 53.25% | $1.48B | +0.08% | 0.33% |
| ORC | 53.18% | $615.55M | +6.95% | 18.46% |
| ALG | 53.03% | $2.30B | +4.01% | 0.55% |
| ORA | 52.69% | $4.80B | +20.68% | 0.61% |
| MMI | 52.67% | $1.58B | +23.86% | 1.24% |
| FUBO | 52.66% | $474.41M | -54.49% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| MSDL | -0.09% | $1.83B | +0.66% | 7.26% |
| RSG | 0.14% | $66.05B | +31.79% | 1.04% |
| LPLA | 0.28% | $23.55B | +38.13% | 0.38% |
| WRAP | 0.32% | $62.86M | -49.45% | 0.00% |
| LITB | -0.45% | $35.48M | -75.45% | 0.00% |
| CAH | 0.57% | $28.64B | +12.14% | 1.70% |
| NHTC | 0.64% | $61.83M | +0.19% | 14.81% |
| GIS | -0.65% | $34.85B | -2.91% | 3.78% |
| VSTA | 0.69% | $204.94M | -39.33% | 0.00% |
| EG | 0.82% | $15.92B | -8.98% | 2.02% |
| CMG | 1.13% | $80.02B | +33.62% | 0.00% |
| NNE | 1.13% | $833.66M | +531.50% | 0.00% |
| JNPR | 1.18% | $11.61B | +30.55% | 2.49% |
| NERV | -1.22% | $14.69M | -58.00% | 0.00% |
| SOC | 1.22% | $1.93B | +74.70% | 0.00% |
| EDN | 1.25% | $813.00M | +161.34% | 0.00% |
| GLP | 1.27% | $1.77B | +51.33% | 5.50% |
| HCI | 1.28% | $1.16B | +29.00% | 1.48% |
| K | 1.37% | $27.77B | +52.50% | 2.79% |
| TEM | 1.38% | $8.50B | 0.00% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| MCK | -13.67% | $78.15B | +35.51% | 0.42% |
| COR | -13.40% | $47.48B | +21.20% | 0.86% |
| TCTM | -12.53% | $8.10M | -42.99% | 0.00% |
| PGR | -12.08% | $149.10B | +57.29% | 0.45% |
| TMUS | -11.62% | $270.63B | +56.92% | 0.83% |
| MNR | -9.36% | $1.66B | -10.71% | 15.90% |
| CBOE | -9.32% | $21.46B | +15.84% | 1.11% |
| HUSA | -9.01% | $16.69M | -11.56% | 0.00% |
| CHD | -8.32% | $27.18B | +19.50% | 1.03% |
| WM | -8.15% | $87.92B | +27.58% | 1.34% |
| PULM | -7.99% | $19.83M | +202.98% | 0.00% |
| CYD | -7.27% | $364.46M | -2.94% | 4.26% |
| BTCT | -6.94% | $42.61M | +353.33% | 0.00% |
| ACGL | -5.69% | $36.00B | +16.84% | 0.00% |
| RNR | -5.68% | $13.74B | +23.09% | 0.58% |
| CME | -5.00% | $82.76B | +9.21% | 1.98% |
| MNOV | -4.68% | $93.19M | +2.15% | 0.00% |
| XGN | -4.55% | $62.26M | +127.74% | 0.00% |
| CCEC | -4.48% | $1.02B | +28.03% | 3.26% |
| VHC | -4.14% | $19.06M | -38.36% | 0.00% |
ETF's related to NTLA
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| GNOM | 77.90% | $70.59M | 0.5% |
| ARKG | 74.75% | $1.13B | 0.75% |
| XBI | 67.00% | $6.58B | 0.35% |
| RSPA | 66.68% | $273.87M | 0% |
| IWC | 66.23% | $933.99M | 0.6% |
| MDYV | 66.21% | $3.25B | 0.15% |
| IWO | 65.09% | $12.56B | 0.24% |
| VTWO | 64.91% | $12.38B | 0.1% |
| IWM | 64.76% | $75.73B | 0.19% |
| IBB | 64.46% | $6.66B | 0.45% |
| NUSC | 63.82% | $1.27B | 0.31% |
| ESML | 63.44% | $1.90B | 0.17% |
| PRFZ | 63.19% | $2.65B | 0.39% |
| ISCG | 63.09% | $640.00M | 0.06% |
| KOMP | 63.05% | $2.09B | 0.2% |
| SMMD | 62.61% | $1.24B | 0.15% |
| VBR | 62.35% | $32.03B | 0.07% |
| PTH | 62.31% | $143.31M | 0.6% |
| VBK | 62.28% | $19.31B | 0.07% |
| IWN | 62.26% | $13.17B | 0.24% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XHLF | -0.09% | $874.27M | 0.03% |
| TBIL | -0.12% | $4.38B | 0.15% |
| BOXX | 0.16% | $4.43B | 0.1949% |
| HIGH | -0.38% | $302.78M | 0.51% |
| DBO | 0.69% | $217.57M | 0.77% |
| HDRO | 1.19% | $164.26M | 0.3% |
| BSCO | 1.28% | $2.35B | 0.1% |
| TBLL | 1.39% | $1.92B | 0.08% |
| XBIL | -1.44% | $637.70M | 0.15% |
| FMF | -1.47% | $244.61M | 0.95% |
| DBE | 1.64% | $50.13M | 0.77% |
| CLOI | 1.66% | $715.40M | 0.4% |
| JBBB | -2.41% | $1.26B | 0.49% |
| KRBN | 2.85% | $242.47M | 0.85% |
| MINT | -3.54% | $11.62B | 0.35% |
| DBMF | -3.76% | $1.02B | 0.85% |
| SGOV | 4.17% | $27.53B | 0.09% |
| CSHI | 4.22% | $482.85M | 0.38% |
| IBHD | 4.26% | $327.80M | 0.35% |
| COMT | 4.30% | $829.06M | 0.48% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -54.43% | $388.04M | 1.43% |
| VIXY | -29.86% | $195.31M | 0.85% |
| USDU | -25.96% | $201.97M | 0.5% |
| UUP | -23.75% | $309.25M | 0.77% |
| AGZD | -17.56% | $142.76M | 0.23% |
| CTA | -15.91% | $350.27M | 0.78% |
| TAIL | -14.90% | $67.98M | 0.59% |
| EQLS | -11.13% | $76.08M | 1% |
| KCCA | -7.94% | $220.51M | 0.87% |
| KMLM | -7.86% | $353.87M | 0.9% |
| DBA | -7.64% | $755.88M | 0.93% |
| WEAT | -7.50% | $120.27M | 0.28% |
| BILZ | -6.63% | $563.02M | 0.14% |
| DBMF | -3.76% | $1.02B | 0.85% |
| MINT | -3.54% | $11.62B | 0.35% |
| JBBB | -2.41% | $1.26B | 0.49% |
| FMF | -1.47% | $244.61M | 0.95% |
| XBIL | -1.44% | $637.70M | 0.15% |
| HIGH | -0.38% | $302.78M | 0.51% |
| TBIL | -0.12% | $4.38B | 0.15% |
News
Yahoo
Intellia Therapeutics ( (NTLA) ) just unveiled an announcement. Intellia Therapeutics has unveiled promising Phase 1 clinical trial results for Nexiguran Ziclumeran, a CRISPR-based gene-editing therapy aimed at treating transthyretin amyloidosis. The therapy demonstrated significant reduction in serum TTR levels and showed stabilization or improvement in disease markers over 12 months. The trial highlights Nexiguran’s potential as a one-time treatment option, with favorable safety and tolerabili
Yahoo
The CF Foundation's investment will propel the development of up to three gene correction programmes.
Yahoo
Wells Fargo lowered the firm’s price target on Intellia Therapeutics (NTLA) to $70 from $80 and keeps an Overweight rating on the shares. The firm notes that Phase 1 ATTR-CM data for nex-z compare well vs. historical data shown by silencers and stabilizers, despite having a greater proportion of patients with more severe disease. Wells thinks this should bode well for Phase 3 success. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
SeekingAlpha
Intellia's Phase 3 trial for NTLA-2002 shows promise, but limitations warrant caution. See why we believe NTLA stock is hold rated.
Yahoo
Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in Chicago.
Yahoo
Phase 1 data indicate Intellia’s medicine could be a powerful treatment for a cardiac form of ATTR amyloidosis. But rival drugs are further ahead.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.